Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have received an average recommendation of “Moderate Buy” from the sixteen brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $199.5333.

PVLA has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Stephens reiterated an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Chardan Capital reissued a “buy” rating and set a $240.00 target price on shares of Palvella Therapeutics in a research report on Thursday, May 21st. HC Wainwright boosted their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Finally, Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $238,512.42. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 17.20% of the company’s stock.

Institutional Trading of Palvella Therapeutics

A number of large investors have recently made changes to their positions in the company. KBC Group NV acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at approximately $28,000. Group One Trading LLC lifted its holdings in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at $36,000. JPMorgan Chase & Co. boosted its position in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Palvella Therapeutics during the second quarter worth $85,000. Institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $157.24 on Monday. The company’s 50 day moving average price is $125.26 and its 200 day moving average price is $115.30. Palvella Therapeutics has a 52 week low of $29.38 and a 52 week high of $161.38. The company has a market capitalization of $2.25 billion, a PE ratio of -37.71 and a beta of -0.20.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, equities analysts forecast that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.